Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings
Julia Malicki, Amelia Baltes, Christopher R. Nicholas, David Horton, Paul R. Hutson, Randall Brown
Psychedelic Medicine December 1, 2023 DOI: 10.1089/psymed.2023.0012 via OpenAlex
Summary
AI-generated from the abstractA clinical trial found that giving psilocybin together with buprenorphine to people with opioid use disorder was safely tolerated and did not interfere with buprenorphine's effectiveness or psilocybin's subjective effects. The study faced feasibility challenges that required changes to the participant pool and eligibility rules, along with strategies to improve accessibility, reduce burden, and increase generalizability.
Study at a glance
| Characteristics | Clinical trial Peer reviewed |
|---|---|
| Population | People with opioid use disorder |
| Interventions | Psilocybin Buprenorphine |
| Topics | Addiction Psilocybin |
| Keywords | Buprenorphine Hallucinogen Medicine |
| Citations | 7 |
| Registration | NCT05242029 |
| Key finding | Coadministration of psilocybin and buprenorphine was safely tolerated and did not show contraindicating effects on buprenorphine's effectiveness or psilocybin's subjective effects. |
Abstract
Coadministration of psilocybin and buprenorphine was safely tolerated and did not demonstrate contraindicating effects vis-à-vis effectiveness of buprenorphine or the subjective effects of psilocybin. Challenges in feasibility led to modifications in the sample population and eligibility criteria and strategies to improve accessibility, minimize burden, and enhance overall generalizability.clinicaltrials.gov ID: NCT05242029.